|
CA1096187A
(en)
|
1977-04-18 |
1981-02-24 |
Souhei Monden |
Ornament adapted to be fixed by permanent magnets
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
ATE419355T1
(de)
|
1992-02-06 |
2009-01-15 |
Novartis Vaccines & Diagnostic |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
AU6267896A
(en)
|
1995-06-07 |
1996-12-30 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth oftumors
|
|
US7423125B2
(en)
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
|
WO1999037791A1
(en)
|
1998-01-23 |
1999-07-29 |
Vlaams Interuniversitair Instituut Voor Biotechnologie |
Multipurpose antibody derivatives
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
JP2003512821A
(ja)
|
1999-10-04 |
2003-04-08 |
メディカゴ インコーポレイテッド |
外来性遺伝子の転写調節方法
|
|
WO2002009573A2
(en)
|
2000-07-31 |
2002-02-07 |
The Brigham And Women's Hospital, Inc. |
Prognostic classification of endometrial cancer
|
|
US7432063B2
(en)
|
2002-02-14 |
2008-10-07 |
Kalobios Pharmaceuticals, Inc. |
Methods for affinity maturation
|
|
US20060204966A1
(en)
|
2003-08-01 |
2006-09-14 |
Spector Neil L |
Treatment of cancers expressing p95 erbb2
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
BR122019012028B1
(pt)
|
2004-04-13 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
EP2402374A1
(en)
|
2005-02-07 |
2012-01-04 |
GlycArt Biotechnology AG |
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
MX2007013924A
(es)
|
2005-05-09 |
2008-01-28 |
Glycart Biotechnology Ag |
Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
|
|
TWI323734B
(en)
|
2005-08-19 |
2010-04-21 |
Abbott Lab |
Dual variable domain immunoglobulin and uses thereof
|
|
ES2856451T3
(es)
|
2005-10-11 |
2021-09-27 |
Amgen Res Munich Gmbh |
Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
|
|
CN105709237A
(zh)
|
2005-12-16 |
2016-06-29 |
Ibc 医药公司 |
基于免疫球蛋白的多价生物活性装配体
|
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
PT2155783E
(pt)
|
2007-04-03 |
2013-11-07 |
Amgen Res Munich Gmbh |
Domínio de ligação específico inter-espécies
|
|
KR101589759B1
(ko)
|
2007-04-03 |
2016-01-29 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ｃｄ３―입실론 결합 도메인
|
|
AU2008234019B2
(en)
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
|
ES2342646B1
(es)
|
2008-06-02 |
2011-04-26 |
Institut De Recerca Hospital Universitari Vall Hebron |
Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
|
|
WO2010065568A2
(en)
|
2008-12-01 |
2010-06-10 |
Laboratory Corporation Of America Holdings |
METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
|
|
EP2387717B1
(en)
|
2009-01-15 |
2014-12-10 |
Laboratory Corporation of America Holdings |
Methods of determining patient response by measurement of her-2 expression
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
CA2761777A1
(en)
|
2009-05-14 |
2010-11-18 |
Prometheus Laboratories Inc. |
Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
|
|
RU2570633C2
(ru)
|
2009-05-27 |
2015-12-10 |
Ф.Хоффманн-Ля Рош Аг |
Три- или тетраспецифические антитела
|
|
WO2010141543A1
(en)
|
2009-06-02 |
2010-12-09 |
Targeted Molecular Diagnostics, Llc |
Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
|
JP5744872B2
(ja)
|
2009-08-31 |
2015-07-08 |
ロシュ グリクアート アーゲー |
親和性成熟ヒト化抗ｃｅａモノクローナル抗体
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
SI2330131T1
(sl)
|
2009-12-07 |
2015-02-27 |
Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants |
Protitelesa proti HER2 skrajšani varianti CTF-611
|
|
EP2519544A1
(en)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
LT3075745T
(lt)
|
2011-02-10 |
2018-11-26 |
Roche Glycart Ag |
Mutavę interleukino-2 polipeptidai
|
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
ME03440B
(me)
|
2011-05-21 |
2020-01-20 |
Macrogenics Inc |
Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
|
|
PT2748201T
(pt)
|
2011-08-23 |
2018-02-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas que ativam as células t
|
|
KR101886983B1
(ko)
|
2011-08-23 |
2018-08-08 |
로슈 글리카트 아게 |
2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
JP5925893B2
(ja)
|
2011-08-23 |
2016-05-25 |
ロシュ グリクアート アーゲー |
二重特異性抗原結合分子
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
PL2794905T3
(pl)
|
2011-12-20 |
2020-11-02 |
Medimmune, Llc |
Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
|
|
ES2743399T3
(es)
|
2012-04-20 |
2020-02-19 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
|
WO2014022540A1
(en)
|
2012-08-02 |
2014-02-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent antigen-binding proteins
|
|
AU2013301582B2
(en)
|
2012-08-07 |
2018-09-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
PL2953972T3
(pl)
|
2013-02-05 |
2021-03-08 |
Engmab Sàrl |
Metoda wyboru przeciwciał przeciwko bcma
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
EA201891502A1
(ru)
|
2013-02-26 |
2018-12-28 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
EP2968552B1
(en)
|
2013-03-14 |
2020-03-11 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
|
KR20150132332A
(ko)
|
2013-03-15 |
2015-11-25 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
저농도 항체 제형
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
HK1217023A1
(zh)
|
2013-05-28 |
2016-12-16 |
Numab Innovation Ag |
新型抗体
|
|
CN104418947A
(zh)
*
|
2013-09-11 |
2015-03-18 |
香港大学 |
抗her2和抗-igf-ir的双特异性抗体及其用途
|
|
KR102630750B1
(ko)
|
2013-12-17 |
2024-01-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
|
KR102357961B1
(ko)
|
2013-12-17 |
2022-02-08 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
KR102411972B1
(ko)
|
2014-08-04 |
2022-06-23 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
AU2015308527C1
(en)
|
2014-08-29 |
2021-07-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
JP2017536341A
(ja)
*
|
2014-10-09 |
2017-12-07 |
エンクマフ アーゲー |
卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
|
|
EP3204415B1
(en)
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
RS60615B1
(sr)
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
CN107074955B
(zh)
|
2014-11-20 |
2021-06-22 |
豪夫迈·罗氏有限公司 |
针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
PT3331910T
(pt)
|
2015-08-03 |
2020-03-24 |
Engmab Sarl |
Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
|
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
WO2017055318A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cd33xcd3 bispecific t cell activating antigen binding molecules
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
IL257696B2
(en)
|
2015-12-09 |
2024-11-01 |
Hoffmann La Roche |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP3555620A1
(en)
*
|
2016-12-13 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
SG11201908784TA
(en)
*
|
2017-03-27 |
2019-10-30 |
Hoffmann La Roche |
Improved antigen binding receptor formats
|